Endoscopic Retrograde Cholangiopancreatography Market By Product Type (ERCP Instruments {Endoscopes, Catheters, Guidewires, Sphincterotomes}, ERCP Devices {Contrast Agents, Stents, Biliary Balloon Dilators}, Endoscopy Systems {Video Endoscopy Systems, Fiber-optic Endoscopy Systems}), By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation), By Application (Diagnostic Applications {Pancreatic Disorders Diagnosis, Biliary Disorders Diagnosis}, Therapeutic Applications {Stone Removal, Stent Placement, Biopsy Collection, Dilation of Narrowed Ducts, Removal of Tumors}), By End-user (Hospitals, Ambulatory Surgical Centers, Diagnostic and Research Centers, Other), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Endoscopic Retrograde Cholangiopancreatography market accounted for USD 2.27 Billion in 2024 and is expected to reach USD 5.46 Billion by 2035, growing at a CAGR of around 8.3% between 2025 and 2035. The endoscopic retrograde cholangiopancreatography market encompasses any innovation and products manufactured to execute ERCP. This category comprises endoscopes, fluoroscopes, contrast agents, and other tools required for the process known to patients as a colonoscopy.

The ERCP procedure is applied in cases of increasing incidences of gastrointestinal diseases such as gallstones, bile duct stricture, and pancreatic disorders. The main drivers include enhanced endoscopies, increasing consciousness of minimally invasive procedures, and expanding utilization of ERCP diagnostics and interventions. It also experiences some other challenges, such as the high cost of equipment and the need for professional personnel.

Report Scope:

Market Dynamics

  The rising incidence of biliary and pancreatic diseases increases ERCP demand.

The rise in incidences of diseases related to biliary and pancreatic ducts has been identified as a main factor that is pushing the endoscopic retrograde cholangiopancreatography market forward. ERCP is a special procedure used to treat conditions such as gallstones, pancreatitis, bile duct obstruction, and others. These diseases are gradually becoming prevalent in the global community, thus increasing the need for the performance of ERCP.

The American Cancer Society policymakers predict that 41,260 people in the USA will be newly diagnosed with liver cancer and intrahepatic bile duct cancer in 2022. Moreover, through its global sources, the World Health Organization reveals that cancer is the second killer disease around the world, leading to 9.6 million deaths in 2018. These figures only prove the rising incidence of biliary and pancreatic diseases, which in turn resulted in a higher requirement for ERCP operations.

Technological advancements enhance procedure accuracy and reduce complications.

The growth of the market can be attributed to the importance of technological developments in refining the scope and safety of endoscopic retrograde cholangiopancreatography procedures. The targeted incorporation of high-definition imaging, single-operator cholangioscopy, and 3D-reconstructed imaging has immensely advanced the accuracy of cholangiopancreatography for the diagnosis of biliary and pancreatic diseases.

However, newer techniques in ERCP have eliminated some of the problems encountered earlier, like perforation and infection. An NIH-sponsored study conducted said the implementation of advanced imaging during ERCP has reduced the complication rates by thirty percent to include pancreatitis. These technological advancements are anticipated to keep pushing the need for ERCP procedures, hence enhancing the conditions of the market for investment and development.

High procedure costs limit accessibility for lower-income patients.

Poor affordability of high procedure costs for ERCP limits the accessibility of the endoscopic retrograde cholangiopancreatography market for lower-end consumers. ERCP specifically is applied in the diagnosis and treatment of bile and pancreatic ducts, and it requires special equipment, expertise, and usually hospitalization, thus making it pricey. Among the challenges actors face are issues to do with costs, particularly the high costs that the procedure incurs which can only be afforded by those who have comprehensive insurance or adequate financial standing.

In many parts of the world, this excludes it to serve only the wealthy patients or those with insurance that covers the full amount for the procedure. Consequently, various low-income clients cannot attempt ERCP or must use suboptimal methods, deepening health inequalities. But that also means that there are a lot of unmet needs, and people receive diagnoses and treatment too late; relative economic status negatively affects the health of people discriminated against.

The development of disposable devices enhances safety and reduces infection risks.

One potential for the advancement of single-use devices relates to endoscopic retrograde cholangiopancreatography (ERCP), which is a significant opportunity for the market, where there is a considerable scope to improve patient safety and decrease the threat of infections. Before the current approach, ERCP was performed with reusable endoscopes and accessories, which, despite being cleaned and sterilized, had the possibility of being contaminated. Reusable devices, which include endoscopes, cannulas, and others that come into contact with the body of a patient, present this problem, but disposable devices diminish such risk through the exclusion of cross-infection between patients.

Besides promoting better infection control, this development also optimizes the working of healthcare environments, as the reuse of many pieces of equipment reduces the amount of reprocessing and sterilization required. Since more healthcare facilities are focusing on the safety of patients, the use of disposable devices in ERCP may contribute to market growth due to this demand and the potential for enhancing the efficacy of the procedures themselves.

Emerging markets present significant growth potential for ERCP procedures.

The opportunity for the growth of the ERCP market in developing countries is high since there is a gradually rising incidence of gastrointestinal diseases and the need for improved care systems. Importantly, there is growing knowledge of ERCP across various parts of the world that have relatively explored healthcare systems, primarily in the diagnosis and management of diseases affecting the biliary and pancreatic tract.

A growing middle-class population in emerging economies like India, China, and Brazil, as well as other parts of the world, is a major factor in the growing popularity of highly sophisticated procedures, including ERCP. Also, better transport to health facilities coupled with increasing government support in bolstering the medical sector helps propagate integrated endoscopic retrograde cholangiopancreatography (ERCP) markets across these global regions. This is due to the increased accessibility of cheap medical equipment, thus increasing the possibility of the incorporation of ERCP by other healthcare institutions.

Industry Experts Opinion

The scope of Duodeno demonstrates our commitment to improving safety for the millions of patients each year who require an ERCP. Our single-use endoscopes eliminate infection and cross-contamination risk.”

• Dr. Juan Tejada, a gastroenterologist and advanced endoscopist at Memorial Health System in Marietta

Segment Analysis

Based on the product type, the Endoscopic Retrograde Cholangiopancreatography Market is classified into ERCP Instruments, ERCP Devices, and Endoscopy Systems. The largest segment in the Endoscopic Retrograde Cholangiopancreatography market is usually the ERCP Instruments segment, more specifically endoscopes. In particular, these instruments are indispensable for the ERCP method, with the help of which certain conditions of the bile ducts, pancreas, and gallbladder are diagnosed and treated using an endoscope.

Endoscopes are flexible sigmoidoscopes used as the major instruments in addressing ERCP procedures. They enable the direct visualization of the biliary and pancreatic ducts and are useful in the diagnosis and mapping of the ducts to perform procedures such as stone extraction, stenting, and biopsy. Since endoscopic treatment for such conditions as bile duct stones, strictures, and pancreatitis still requires ERCP procedures, the sales of high-quality, sophisticated endoscopes remain the key growth factor in this market segment.

Based on the procedure, the Endoscopic Retrograde Cholangiopancreatography Market is classified into Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, and Pancreatic Duct Dilation. The segment that is traditionally most dominant in the ERCP market by procedure is generally Biliary Sphincterotomy. This procedure is common during ERCP because of complications such as bile duct stones or strictures. It may involve creating a small cut on the sphincter of Oddi so that it is possible to clear stones or put stents, within the bile ducts.

The Biliary Sphincterotomy is an essential treatment for confronting patients with obstructive jaundice or other bile duct disorders since it positively contributes to the removal of obstructions and facilitates bile flow. ERCP is a highly successful procedure for treating various biliary disorders to which a very high success rate connected with the effectiveness of the procedure corresponds in the market. The expansion of the scope of its importance can be explained by the growing number of people with gallstones and obstructions of bile ducts.

Regional Analysis

The North American endoscopic retrograde cholangiopancreatography market is leading due to its well-developed healthcare sector and high preference for minimally invasive procedures. It also boasts good health facilities and very many qualified medical practitioners in the region. The increasing incidence of pancreatic and biliary illnesses, including gallstones and pancreatitis, leads to a higher need for ERCP.

Furthermore, there is an existence of major market players and continuous technological developments in endoscopy equipment in the region. To date, North America remains the most active in investing in innovations in ERCP techniques, given the emphasis of its countries on research. A high healthcare expenditure is used effectively for the treatment to reach the patients within the region. In addition, an increase in the choice and knowledge about minimally invasive solutions among patients also contributes to market development. Due to more favorable reimbursement policies and an increased clinical utilization of ERCP, North America continues to occupy the leading position in the global market.

The Asia-Pacific region holds the largest CAGR in the ERCP market due to factors such as technological improvements in the setup of endoscopy and an increased incidence of gastrointestinal diseases. China, India, and Japan are experiencing an increasing demand for ERCP procedures due to the changing prevalence of biliary diseases, including gallstones and pancreatitis. They incorporate the extended healthcare availability across the region, especially in emerging markets, as another driver of the market.

Also, the increasing use of newer medical technologies and an increased consciousness among patients about endoscopic procedures are driving demand. It is also economically advantageous in comparison to Western countries in terms of options’ expense, which provides the population with access to ERCP treatments. Additional players are also focusing on government policies to enhance the overall healthcare vertical and the increasing demand and availability of professional forces in the healthcare BPO market, supplementing the demand for market growth. Besides, with applied upgrades in overall healthcare expenditures and easier access to modern technologies, the Asia-Pacific region is set to become a dominant buyer for ERCP.

Competitive Landscape

The structure of the market depends on key stakeholders such as Olympus Corporation, Boston Scientific, Medtronic, and Cook Medical, among others, dealing in the endoscopic retrograde cholangiopancreatography (ERCP) market. These companies provide constant innovation with the kind of products they develop and strategic partnerships.

New products have included Olympus's release of its new ERCP endoscopes with better image resolution for higher diagnostic yield, along with Boston Scientific’s new Exalt™ Model D Single-Use Duodenoscope that is aimed at minimizing infection risks. Medtronic's market portfolio has been bolstered by its purchase of complementary technologies, and the trend of integrating the newest features has gained recognition.

Endoscopic Retrograde Cholangiopancreatography Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In March 2024, NTT Corporation (NTT) and Olympus Corporation initiated a joint venture to carry out a demonstration experiment of a cloud-based endoscopy system. This cutting-edge system enables image processing via cloud computing, representing a major leap in medical technology. The partnership between NTT and Olympus to develop this cloud endoscopy system signifies a groundbreaking achievement in the field of medical imaging.
• In November 2023, HOYA Corporation completed the acquisition of the remaining shares of WASSENBURG Medical B.V., becoming its sole shareholder. This acquisition strengthened HOYA's position in the medical equipment sector, particularly in endoscope reprocessing. The combined expertise of HOYA Corporation, PENTAX Medical, and WASSENBURG Medical is expected to drive further advancements in endoscope reprocessing technology and services.

Report Coverage:

By Product Type

• ERCP Instruments
  • Endoscopes
  • Catheters
  • Guidewires
  • Sphincterotomes
• ERCP Devices
  • Contrast Agents
  • Stents
  • Biliary Balloon Dilators
• Endoscopy Systems
  • Video Endoscopy Systems
  • Fiber-optic Endoscopy Systems

By Procedure

• Biliary Sphincterotomy
• Biliary Stenting
• Biliary Dilatation
• Pancreatic Sphincterotomy
• Pancreatic Duct Stenting
• Pancreatic Duct Dilation

By Application

• Diagnostic Applications
  • Pancreatic Disorders Diagnosis
  • Biliary Disorders Diagnosis
• Therapeutic Applications
  • Stone Removal
  • Stent Placement
  • Biopsy Collection
  • Dilation of Narrowed Ducts
  • Removal of Tumors

End-user

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic and Research Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Olympus Corporation
• Boston Scientific Corporation
• Medtronic plc
• Cook Medical
• Fujifilm Holdings Corporation
• Conmed Corporation
• Karl Storz SE & Co. KG
• Pentax Medical (HOYA Group)
• STERIS plc
• Ambu A/S
• Smith & Nephew plc
• Ethicon (Johnson & Johnson)
• EndoMed Systems GmbH
• Taewoong Medical Co., Ltd.
• Cantel Medical Corporation

Frequently Asked Questions (FAQs)